The naive question: why would a cutting-edge blood-disease therapy try to switch on a gene you stopped using as a newborn? It sounds backwards. It's actually the most elegant trick in the field.
Before birth, your body makes fetal hemoglobin to carry oxygen. Around birth, it flips a switch and changes to adult hemoglobin. For most people that's fine. But in sickle cell and beta-thalassemia, the adult version is the broken one — and the fetal version, if you could turn it back on, works perfectly well.
So instead of repairing the broken adult gene directly — hard and risky — therapies reawaken the fetal gene. It's like a power outage where, rather than fixing the failed main line, you switch back to a working backup generator you'd mothballed.
The patents target the switch precisely. Publication US20230310506A1 covers a method for activating expression of the gamma-globin gene — gamma-globin being the fetal-hemoglobin component. Turn that gene back on and healthy hemoglobin returns.
Making it a therapy means doing this in the right cells. Stanford's grant US11634732B2 covers gene-corrected primary cells as a medicine, and CSL Behring Gene Therapy's US11795461B2 covers treating beta-hemoglobinopathies — the disease family this switch addresses.
The short version: the fetal hemoglobin switch is a healthy backup the body turns off after birth. In these blood diseases, reawakening it sidesteps the broken adult gene entirely — and that switch is exactly what the 2023 patents are built to flip.